drugset / Trial / NCT05524935
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
Phase 2
Active not recruiting
12 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective phase II multi-center trial of the combination of the PARP inhibitor olaparib with the immune checkpoint inhibitor pembrolizumab in advanced uveal melanoma.
Timeline
- Start
- 2022-10-11
- Primary completion
- 2026-07
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaparib | Small molecule | 300 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |